Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
about
Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cellsPhase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell linesA phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group studyA Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors.Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.A novel trial of topotecan, ifosfamide, and carboplatin (TIC) in children with recurrent solid tumors.Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma ModelsCaelyx/Doxil for the treatment of metastatic ovarian and breast cancer.Poly(d,l-lactide-co-glycolide)-chitosan composite particles for the treatment of lung cancer.Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group studyConvection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenograftsPhase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlatesTopotecan-based combination chemotherapy in patients with transformed chronic myelogenous leukemia and advanced myelodysplastic syndromeInhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial.Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs.Topotecan inhibits cancer cell migration by down-regulation of chemokine CC motif receptor 7 and matrix metalloproteinases.Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.Live-cell monitoring of the glutathione-triggered release of the anticancer drug topotecan on gold nanoparticles in serum-containing media.BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models.Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity.Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer.Phase I study of sequential administration of topotecan and 5-fluorouracil in patients with advanced malignancies.Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo.Topotecan: a new topoisomerase I inhibiting antineoplastic agent.Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia.Topotecan combined with Ifosfamide, Etoposide, and L-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma.Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system.Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO APhase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.Sequential administration of camptothecin sensitizes human colon cancer HCT116 cells to paclitaxel via p21Cip1/WAF1
P2860
Q24298561-762B204D-9E26-4695-94FF-0244EF34FD9BQ27851478-572307A9-10FF-42E8-9112-8D36B9DE1AAFQ28469349-22B62905-96C8-42F3-BFBC-97185F6200C1Q30371410-A52B9188-54E1-470B-9950-166660B87477Q33339062-45538B1B-4D67-4DE2-9C33-AE3DB084A7ECQ33376920-BCE910FC-4C5E-48E2-B1E1-6A030F370F18Q33378252-260F6C30-BD41-4B0B-98BE-464895B55EEAQ33387996-BE7C5C63-C7A9-4270-9248-785601B4C232Q33418620-F5796E4B-2CA7-435E-A1C1-CD207A08FB08Q33649056-52EE1CDD-D676-4AAE-84DC-76FC3F9F60F7Q34734502-E6FECA44-0516-4C6B-8566-C54AC05D15ECQ35524032-FC965805-E4AB-49C5-AD6F-BCD1B33D6ACBQ35565630-FBBD2D70-D5B8-4384-A645-F922D9294426Q35688338-4874F034-03A5-4EB0-9F79-02F10932956AQ35907089-7486C5C9-D132-45D9-A804-6282925DA124Q35937752-62B61C03-901C-40D1-9A27-921FC266EFAFQ36166739-0B328619-B9A5-403F-96B5-8B9B545B92B3Q36560547-917DA600-FCAA-4F86-A668-6BD2DE3D5C2CQ36614907-3FEDB2B8-3DFF-4541-A263-7277920046C2Q37371826-90488360-EDD0-4BDB-BF81-379A4C381457Q37728935-DED5D4BB-01A8-4444-8938-EFF4C8AD7988Q37968253-C14B576D-F433-424D-A265-D19C73F7EBF2Q39375202-777D9E16-DC16-4CC4-BFE8-BA45A7E16B62Q39985326-B306D184-7763-49AA-8A39-729A072762D5Q40184984-7C546BA8-CE72-4237-A5B3-ED318E55888CQ40460534-754B0D60-53DB-4362-8FB9-030399AFF16EQ40490161-B1802BAF-BB1A-49B0-A8E0-3D3089B94712Q40708483-A25C3500-8A82-4896-BE51-FEBCAF6C585CQ40708490-AAEECA99-A1DD-467E-A141-88851A2025B8Q41076904-8536EFA4-7385-48C8-A9CA-5C6E6D058EC6Q42689189-AE6D51C5-8B98-4A56-9BFB-3861A51A295BQ43770759-85196CE3-9EE2-4369-9BAD-BD90CC65874AQ44598660-4C82E783-6EAE-4DED-BFD2-F314EAB1CEB2Q45072628-25A45E78-6B80-4E7F-9B70-D7274224C3EAQ45096277-2649D1FE-B559-4350-B2C8-ECFD1142946EQ46884985-040ADB1D-CE99-4188-B79D-BBBBB918F4A2Q47631494-808F623E-2831-42C4-9BC5-4EC024B96FA1Q55474881-998C11C7-5C6B-41E0-9F2A-4CD1B5B7D394Q58308570-CBC45536-7DE2-482C-AA46-EA108F1D6C59
P2860
Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Cytotoxic effects of topotecan ...... ts in human cancer cell lines.
@en
type
label
Cytotoxic effects of topotecan ...... ts in human cancer cell lines.
@en
prefLabel
Cytotoxic effects of topotecan ...... ts in human cancer cell lines.
@en
P2093
P356
P1476
Cytotoxic effects of topotecan ...... ts in human cancer cell lines.
@en
P2093
Buckwalter CA
Donehower RC
Grochow LB
Peereboom D
Rowinsky EK
Svingen PA
P304
P356
10.1093/JNCI/88.11.734
P407
P577
1996-06-01T00:00:00Z